» Articles » PMID: 31848329

Presence of White Matter Lesions Associated with Diabetes-Associated Cognitive Decline in Male Rat Models of Pre-Type 2 Diabetes

Overview
Journal Med Sci Monit
Date 2019 Dec 19
PMID 31848329
Citations 5
Authors
Affiliations
Soon will be listed here.
Abstract

BACKGROUND The aim of this study was to determine the association between white matter lesions (WML) and diabetes-associated cognitive decline (DACD) in rat models of type 2 diabetes (T2DM). MATERIAL AND METHODS Sixty Sprague-Dawley male rats were divided into 4 groups: control, control+metformin, T2DM, and T2DM+metformin groups. The T2DM groups were fed a diet high in fat and glucose to induce impaired glucose tolerance (IGT) and then were injected with streptozotocin to induce T2DM. The Morris water maze test was used to evaluate cognitive function. Brain diffusion tensor imaging scans were performed for WML. The expression of myelin basic protein (MBP), oligodendrocyte transcription factor 1 (OLIG1), and OLIG2 (markers of brain damage and repair) was determined using immunofluorescence. After IGT, the fractional anisotropy (FA) values of the right thalamus area were significantly lower in both T2DM groups compared with controls. RESULTS Eight weeks after streptozotocin injection, the FA values of the thalamus were lower in the T2DM (bilateral thalamus) group and T2DM+metformin (left thalamus) group than in controls, while the FA values in the left thalamus area were lower in the T2DM+metformin group than in the control and control+metformin groups. The maze escape latency was longer and the number of rats passing through the platform was smaller in the T2DM and T2DM+metformin groups than in the control group. MBP levels were lower and OLIG1 and OLIG2 levels were higher in both T2DM groups than in controls. CONCLUSIONS WML is associated with DACD and appears before the onset of T2DM and signs of DACD and plays a role in diabetes-associated cognitive decline. Metformin reduces WMLs but does not rescue cognitive dysfunction.

Citing Articles

Evaluation of the biological efficiency of Terminalia chebula fruit extract against neurochemical changes induced in brain of diabetic rats: an epigenetic study.

El-Shamarka M, Aboulthana W, Omar N, Mahfouz M Inflammopharmacology. 2024; 32(2):1439-1460.

PMID: 38329710 PMC: 11006788. DOI: 10.1007/s10787-024-01428-9.


The AMPK activator metformin improves recovery from demyelination by shifting oligodendrocyte bioenergetics and accelerating OPC differentiation.

Narine M, Azmi M, Umali M, Volz A, Colognato H Front Cell Neurosci. 2023; 17:1254303.

PMID: 37904733 PMC: 10613472. DOI: 10.3389/fncel.2023.1254303.


Glial-neuron crosstalk in health and disease: A focus on metabolism, obesity, and cognitive impairment.

Henn R, Noureldein M, Elzinga S, Kim B, Savelieff M, Feldman E Neurobiol Dis. 2022; 170:105766.

PMID: 35584728 PMC: 10071699. DOI: 10.1016/j.nbd.2022.105766.


Role of White Matter Hyperintensities and Related Risk Factors in Vascular Cognitive Impairment: A Review.

Chen Y, Wang X, Guan L, Wang Y Biomolecules. 2021; 11(8).

PMID: 34439769 PMC: 8391787. DOI: 10.3390/biom11081102.


Three-dimensional-arterial spin labeling perfusion correlation with diabetes-associated cognitive dysfunction and vascular endothelial growth factor in type 2 diabetes mellitus rat.

Shao J, Wang J, He Q, Yang Y, Zou Y, Su W World J Diabetes. 2021; 12(4):499-513.

PMID: 33889293 PMC: 8040076. DOI: 10.4239/wjd.v12.i4.499.

References
1.
Takebayashi H, Nabeshima Y, Yoshida S, Chisaka O, Ikenaka K, Nabeshima Y . The basic helix-loop-helix factor olig2 is essential for the development of motoneuron and oligodendrocyte lineages. Curr Biol. 2002; 12(13):1157-63. DOI: 10.1016/s0960-9822(02)00926-0. View

2.
Annoni J, Khateb A, Gramigna S, Staub F, Carota A, Maeder P . Chronic cognitive impairment following laterothalamic infarcts: a study of 9 cases. Arch Neurol. 2003; 60(10):1439-43. DOI: 10.1001/archneur.60.10.1439. View

3.
van Harten B, de Leeuw F, Weinstein H, Scheltens P, Biessels G . Brain imaging in patients with diabetes: a systematic review. Diabetes Care. 2006; 29(11):2539-48. DOI: 10.2337/dc06-1637. View

4.
Jellinger K . The pathology of ischemic-vascular dementia: an update. J Neurol Sci. 2002; 203-204:153-7. DOI: 10.1016/s0022-510x(02)00282-4. View

5.
Tankisi H, Pugdahl K, Johnsen B, Fuglsang-Frederiksen A . Correlations of nerve conduction measures in axonal and demyelinating polyneuropathies. Clin Neurophysiol. 2007; 118(11):2383-92. DOI: 10.1016/j.clinph.2007.07.027. View